News Novartis pulls plug on landmark UK cholesterol trial ORION-17 study has been abandoned, with Novartis opting instead for a smaller global trial.
News Double blow for Sangamo as Novartis, Biogen exit deals The two deals for gene-modifying candidates were worth up to $3.1 billion including milestones.
News AbbVie’s Skyrizi hits the spot in refractory psoriasis Antibody works when IL-17 inhibitors Like Novartis' Cosentyx and Lilly's Taltz fail.
News Sandoz bolsters biosimilars with $400m Slovenia plant New facility will be based at Sandoz' Lek subsidiary, and employ 300 staff when completed.
News FDA removes leash from Verzenio in early breast cancer Drug can now be used as adjuvant therapy without Ki-67 testing, taking a brake off prescribing.
News French court overturns €444m fine for Novartis, Roche Says companies did not abuse a market position to push Lucentis over off-label Avastin in AMD.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
